Neuroblastoma: biological insights into a clinical enigma (original) (raw)

• Knudson, A. G. J. & Strong, L. C. Mutation and cancer: neuroblastoma and pheochromocytoma. Am. J. Hum. Genet. 24, 514–522 (1972).
  PubMed PubMed Central Google Scholar
• Kushner, B. H., Gilbert, F. & Helson, L. Familial neuroblastoma: case reports, literature review, and etiologic considerations. Cancer 57, 1887–1893 (1986).
  Article CAS PubMed Google Scholar
• Maris, J. M. & Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17, 2264–2279 (1999).
  Article CAS PubMed Google Scholar
• Kushner, B. H. & Helson, L. Monozygotic siblings discordant for neuroblastoma: etiologic implications. J. Pediatr. 107, 405–409 (1985).
  Article CAS PubMed Google Scholar
• Kushner, B. H., Hajdu, S. I. & Helson, L. Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature. J. Clin. Oncol. 3, 117–120 (1985).
  Article CAS PubMed Google Scholar
• Maris, J. M. et al. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res. 56, 3421–3425 (1996).
  CAS PubMed Google Scholar
• Weiss, M. J. et al. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med. Pediatr. Oncol. 35, 526–530 (2000).
  Article CAS PubMed Google Scholar
• Bown, N. P., Pearson, A. D. J. & Reid, M. M. High incidence of constitutional balanced translocations in neuroblastoma. Cancer Genet. Cytogenet. 69, 166–167 (1993).
  Article CAS PubMed Google Scholar
• Biegel, J. A. et al. Constitutional 1p36 deletion in a child with neuroblastoma. Am. J. Hum. Genet. 52, 176–182 (1993).
  CAS PubMed PubMed Central Google Scholar
• Laureys, G. et al. Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers. Oncogene 10, 1087–1093 (1995).
  CAS PubMed Google Scholar
• White, P. S. et al. Detailed molecular analysis of 1p36 in neuroblastoma. Med. Pediatr. Oncol. 36, 37–41 (2001).
  Article CAS PubMed Google Scholar
• Maris, J. M. et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 62, 6651–6658 (2002). The first report of linkage analysis, identifying a candidate locus on 16p12-13.
  CAS PubMed Google Scholar
• Kaneko, Y. et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res. 47, 311–318 (1987). The first report to associate karyotypic pattern with stage and prognosis, and the first to show the association of near-triploid tumours in infants with whole chromosome gains.
  CAS PubMed Google Scholar
• Kaneko, Y. et al. Current urinary mass screening or catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study. J. Clin. Oncol. 8, 2005–2013 (1990).
  Article CAS PubMed Google Scholar
• Look, A. T., Hayes, F. A., Nitschke, R., McWilliams, N. B. & Green, A. A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 311, 231–235 (1984). The first report to show the prognostic significance of tumour-cell DNA content in infants with neuroblastoma.
  Article CAS PubMed Google Scholar
• Look, A. T. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma. A Pediatric Oncology Group Study. J. Clin. Oncol. 9, 581–591 (1991).
  Article CAS PubMed Google Scholar
• Kaneko, Y. & Knudson, A. G. Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosom. Cancer 29, 89–95 (2000).
  Article CAS PubMed Google Scholar
• Schwab, M. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305, 245–248 (1983). Reports the cloning of the MYCN proto-oncogene as the gene amplified in neuroblastoma cell lines and a primary tumour.
  Article CAS PubMed Google Scholar
• Schwab, M. et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308, 288–291 (1984).
  Article CAS PubMed Google Scholar
• Corvi, R., Amler, L. C., Savelyeva, L., Gehring, M. & Schwab, M. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc. Natl Acad. Sci. USA 91, 5523–5527 (1994).
  Article CAS PubMed Google Scholar
• Schneider, S. S. et al. Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. Mol. Cell. Biol. 12, 5563–5570 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Brodeur, G. M. & Fong, C. T. Molecular biology and genetics of human neuroblastoma. Cancer Genet. Cytogenet. 41, 153–174 (1989).
  Article CAS PubMed Google Scholar
• Reiter, J. L. & Brodeur, G. M. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics 32, 97–103 (1996).
  Article CAS PubMed Google Scholar
• Reiter, J. L. & Brodeur, G. M. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosom. Cancer 23, 134–140 (1998).
  Article CAS PubMed Google Scholar
• Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121–1124 (1984). Amplification of the MYCN oncogene is strongly associated with advanced stages of disease in neuroblastoma.
  Article CAS PubMed Google Scholar
• Seeger, R. C. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313, 1111–1116 (1985). The first report to show the adverse prognostic significance of MYCN amplification in neuroblastoma patients.
  Article CAS PubMed Google Scholar
• Brodeur, G. M., Maris, J. M., Yamashiro, D. J., Hogarty, M. D. & White, P. S. Biology and genetics of human neuroblastomas. J. Pediatr. Hematol. Oncol. 19, 93–101 (1997).
  Article CAS PubMed Google Scholar
• Brodeur, G. M. & Ambros, P. F. in Neuroblastoma (eds Brodeur, G. M., Sawada, T., Tsuchida, Y. & Voûte, P. A.) 355–369 (Elsevier Science B. V., Amsterdam, 2000).
  Google Scholar
• Brodeur, G. M. & Maris, J. M. in Principles and Practice of Pediatric Oncology (eds Pizzo, P. & Poplack, D.) 895–937 (2002).
  Google Scholar
• Brodeur, G. M. in The Genetic Basis of Human Cancer (eds Vogelstein, B. & Kinzler, K. W.) 751–772 (McGraw–Hill, Inc., New York, 2002).
  Google Scholar
• Brodeur, G. M. et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 47, 4248–4253 (1987).
  CAS PubMed Google Scholar
• Seeger, R. C. et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog. Clin. Biol. Res. 271, 41–49 (1988).
  CAS PubMed Google Scholar
• Norris, M. D. et al. Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. Eur. J. Cancer 33, 1911–1916 (1997).
  Article CAS PubMed Google Scholar
• Shohet, J. M. et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 62, 1123–1128 (2002).
  CAS PubMed Google Scholar
• Nakagawara, A., Arima, M., Azar, C. G., Scavarda, N. J. & Brodeur, G. M. Inverse relationship between TRK expression and N-MYC amplification in human neuroblastomas. Cancer Res. 52, 1364–1368 (1992).
  CAS PubMed Google Scholar
• Wada, R. K. et al. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer 72, 3346–3354 (1993).
  Article CAS PubMed Google Scholar
• Cohn, S. L. et al. High levels of N-myc protein in a neuroblastoma cell line lacking N-myc amplification. Prog. Clin. Biol. Res. 366, 21–27 (1991).
  CAS PubMed Google Scholar
• Sivak, L. E. et al. Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 15, 1937–1946 (1997).
  Article CAS PubMed Google Scholar
• Chan, H. S. et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin. Cancer Res. 3, 1699–1706 (1997).
  CAS PubMed Google Scholar
• Bordow, S. B., Norris, M. D., Haber, P. S., Marshall, G. M. & Haber, M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J. Clin. Oncol. 16, 3286–3294 (1998).
  Article CAS PubMed Google Scholar
• Cohn, S. L. et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol. 18, 3604–3613 (2000).
  Article CAS PubMed Google Scholar
• Fong, C. T. et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc. Natl Acad. Sci. USA 86, 3753–3757 (1989).
  Article CAS PubMed Google Scholar
• Gehring, M., Berthold, F., Edler, L., Schwab, M. & Amler, L. C. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res. 55, 5366–5369 (1995).
  CAS PubMed Google Scholar
• Caron, H. et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N. Engl. J. Med. 334, 225–230 (1996).
  Article CAS PubMed Google Scholar
• Maris, J. M. et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J. Clin. Oncol. 18, 1888–1899 (2000).
  Article CAS PubMed Google Scholar
• Jinbo, T., Iwamura, Y., Kaneko, M. & Sawaguchi, S. Coamplification of the L-myc and N-myc oncogenes in a neuroblastoma cell line. Jpn. J. Cancer Res. 80, 299–301 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Corvi, R. et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 10, 1081–1086 (1995).
  CAS PubMed Google Scholar
• Van Roy, N. et al. Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. Cancer Genet. Cytogenet. 82, 151–154 (1995).
  Article CAS PubMed Google Scholar
• Brinkschmidt, C. et al. Comparative genomic hybridization (CGH) analysis of neuroblastomas — an important methodological approach in paediatric tumour pathology. J. Pathol. 181, 394–400 (1997).
  Article CAS PubMed Google Scholar
• Lastowska, M. et al. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Genes Chromosom. Cancer 18, 162–169 (1997).
  Article CAS PubMed Google Scholar
• Vandesompele, J. et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosom. Cancer 23, 141–152 (1998).
  Article CAS PubMed Google Scholar
• Caron, H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med. Pediatr. Oncol. 24, 215–221 (1995).
  Article CAS PubMed Google Scholar
• Bown, N. et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340, 1954–1961 (1999). Definitive report of the prevalence and clinical significance of unbalanced 17q gain in neuroblastomas.
  Article CAS PubMed Google Scholar
• Van Roy, N. et al. Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes. Eur. J. Cancer 33, 1974–1978 (1997).
  Article CAS PubMed Google Scholar
• Lastowska, M. et al. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosom. Cancer 34, 428–436 (2002).
  Article CAS PubMed Google Scholar
• Islam, A. et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617–623 (2000).
  Article CAS PubMed Google Scholar
• Ireland, C. M. Activated N-ras oncogenes in human neuroblastoma. Cancer Res. 49, 5530–5533 (1989).
  CAS PubMed Google Scholar
• Moley, J. F. et al. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas and medullary thyroid cancers. Cancer Res. 51, 1596–1599 (1991).
  CAS PubMed Google Scholar
• Tanaka, T. et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res. 48, 1030–1034 (1988).
  CAS PubMed Google Scholar
• Brodeur, G. M. et al. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 41, 4678–4686 (1981). Definitive report of distal 1p deletions as a genetic change characteristic of neuroblastomas. The clinical significance of deletion of 1p was shown subsequently in large studies.
  CAS PubMed Google Scholar
• White, P. S. et al. A region of consistent deletion in neuroblastoma maps within 1p36.2-3. Proc. Natl Acad. Sci. USA 92, 5520–5524 (1995).
  Article CAS PubMed Google Scholar
• Martinsson, T., Shoberg, P. -M., Hedborg, F. & Kogner, P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 55, 5681–5686 (1995).
  CAS PubMed Google Scholar
• Ejeskar, K. et al. Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med. Pediatr. Oncol. 36, 61–66 (2001).
  Article CAS PubMed Google Scholar
• Caron, H. et al. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosom. Cancer 30, 168–174 (2001).
  Article CAS PubMed Google Scholar
• Bauer, A. et al. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosom. Cancer 31, 228–239 (2001).
  Article CAS PubMed Google Scholar
• Hogarty, M. D. et al. Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med. Pediatr. Oncol. 35, 512–515 (2000).
  Article CAS PubMed Google Scholar
• Maris, J. M. et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med. Pediatr. Oncol. 36, 32–36 (2001).
  Article CAS PubMed Google Scholar
• Ohira, M. et al. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene 19, 4302–4307 (2000).
  Article CAS PubMed Google Scholar
• Chen, Y. Z. et al. Homozygous deletion in a neuroblastoma cell line defined by a high-density STS map spanning human chromosome band 1p36. Genes Chromosom. Cancer 31, 326–332 (2001).
  Article CAS PubMed Google Scholar
• Srivatsan, E. S., Ying, K. L. & Seeger, R. C. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosom. Cancer 7, 32–37 (1993).
  Article CAS PubMed Google Scholar
• Plantaz, D. et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int. J. Cancer 91, 680–686 (2001).
  Article CAS PubMed Google Scholar
• Guo, C. et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 18, 4948–4957 (1999).
  Article CAS PubMed Google Scholar
• Suzuki, T. et al. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res. 49, 1095–1098 (1989).
  CAS PubMed Google Scholar
• Hoshi, M. et al. Detailed deletion mapping of chromosome band 14q32 in human neuroblastoma defines a 1.1-Mb region of common allelic loss. Br. J. Cancer 82, 1801–1807 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Thompson, P. M. et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med. Pediatr. Oncol. 36, 28–31 (2001).
  Article CAS PubMed Google Scholar
• Vogan, K. et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53, 5269–5273 (1993).
  CAS PubMed Google Scholar
• Hosoi, G. et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer 73, 3087–3093 (1994).
  Article CAS PubMed Google Scholar
• Keshelava, N. et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185–6193 (2001).
  CAS PubMed Google Scholar
• Tweddle, D. A., Malcolm, A. J., Bown, N., Pearson, A. D. & Lunec, J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 61, 8–13 (2001).
  CAS PubMed Google Scholar
• Moll, U. M., LaQuaglia, M., Benard, J. & Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl Acad. Sci. USA 92, 4407–4411 (1995).
  Article CAS PubMed Google Scholar
• Moll, U. M. et al. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16, 1126–1137 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Goldman, S. C., Chen, C. Y., Lansing, T. J., Gilmer, T. M. & Kastan, M. B. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol. 148, 1381–1385 (1996).
  CAS PubMed PubMed Central Google Scholar
• Beltinger, C. P., White, P. S., Sulman, E. P., Maris, J. M. & Brodeur, G. M. No CDKN2 mutations in neuroblastomas. Cancer Res. 55, 2053–2055 (1995).
  CAS PubMed Google Scholar
• Iolascon, A. et al. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma. Pediatr. Res. 43, 139–144 (1998).
  Article CAS PubMed Google Scholar
• Kawamata, N., Seriu, T., Koeffler, H. P. & Bartram, C. R. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer 77, 570–575 (1996).
  Article CAS PubMed Google Scholar
• Thompson, P. M. et al. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res. 61, 679–686 (2001).
  CAS PubMed Google Scholar
• Johnson, M. R., Look, A. T., DeClue, J. E., Valentine, M. B. & Lowy, D. R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP Ras. Proc. Natl Acad. Sci. USA 90, 5539–5543 (1993).
  Article CAS PubMed Google Scholar
• The, I. et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nature Genet. 3, 62–66 (1993).
  Article CAS PubMed Google Scholar
• Yano, H. & Chao, M. V. Neurotrophin receptor structure and interactions. Pharm. Acta Helv. 74, 253–260 (2000).
  Article CAS PubMed Google Scholar
• Patapoutian, A. & Reichardt, L. F. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11, 272–280 (2001).
  Article CAS PubMed Google Scholar
• Nakagawara, A. et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. 328, 847–854 (1993). The first report to show the favourable prognostic value of TrkA expression in neuroblastomas. Other reports were reported independently with similar results.
  Article CAS PubMed Google Scholar
• Suzuki, T., Bogenmann, E., Shimada, H., Stram, D. & Seeger, R. C. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J. Natl Cancer Inst. 85, 377–384 (1993).
  Article CAS PubMed Google Scholar
• Kogner, P. et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res. 53, 2044–2050 (1993).
  CAS PubMed Google Scholar
• Ambros, I. M. et al. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N. Engl. J. Med. 334, 1505–1511 (1996).
  Article CAS PubMed Google Scholar
• Ambros, I. M. et al. Neuroblastoma cells provoke Schwann cell proliferation in vitro. Med. Pediatr. Oncol. 36, 163–168 (2001).
  Article CAS PubMed Google Scholar
• Nakagawara, A. & Brodeur, G. M. Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study. Eur. J. Cancer 33, 2050–2053 (1997).
  Article CAS PubMed Google Scholar
• Nakagawara, A., Azar, C. G., Scavarda, N. J. & Brodeur, G. M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell. Biol. 14, 759–767 (1994). The first report to associate TrkB and BDNF expression with high-risk neuroblastomas that have MYCN amplification.
  Article CAS PubMed PubMed Central Google Scholar
• Acheson, A. et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 374, 450–453 (1995).
  Article CAS PubMed Google Scholar
• Matsumoto, K., Wada, R. K., Yamashiro, J. M., Kaplan, D. R. & Thiele, C. J. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res. 55, 1798–1806 (1995).
  CAS PubMed Google Scholar
• Eggert, A. et al. Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Med. Pediatr. Oncol. 35, 569–572 (2000).
  Article CAS PubMed Google Scholar
• Ho, R. et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 62, 6462–6466 (2002).
  CAS PubMed Google Scholar
• Yamashiro, D. J., Nakagawara, A., Ikegaki, N., Liu, X. -G. & Brodeur, G. M. Expression of TrkC in favorable human neuroblastomas. Oncogene 12, 37–41 (1996).
  CAS PubMed Google Scholar
• Ryden, M. et al. Expression of mRNA for the neurotrophin receptor TrkC in neuroblastomas with favourable tumour stage and good prognosis. Br. J. Cancer 74, 773–779 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Casaccia-Bonnefil, P., Gu, C. & Chao, M. V. Neurotrophins in cell survival/death decisions. Adv. Exp. Med. Biol. 468, 275–282 (1999).
  Article CAS PubMed Google Scholar
• Hempstead, B. L. The many faces of p75NTR. Curr. Opin. Neurobiol. 12, 260–267 (2002).
  Article CAS PubMed Google Scholar
• Goldstein, L. J. et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J. Clin. Oncol. 8, 128–136 (1990).
  Article CAS PubMed Google Scholar
• Chan, H. S. et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325, 1608–1614 (1991).
  Article CAS PubMed Google Scholar
• Norris, M. D. et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N. Engl. J. Med. 334, 231–238 (1996).
  Article CAS PubMed Google Scholar
• Hiyama, E. et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med. 1, 249–255 (1995).
  Article CAS PubMed Google Scholar
• Brodeur, G. M. Do the ends justify the means? Nature Med. 1, 203–205 (1995).
  Article CAS PubMed Google Scholar
• Brodeur, G. M. & Castle, V. P. in Apoptosis and Cancer Chemotherapy (eds Hickman, J. A. & Dive, C.) 305–318 (Humana, New Jersey, 1999).
  Book Google Scholar
• Bunone, G., Mariotti, A., Compagni, A., Morandi, E. & Della Valle, G. Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells. Oncogene 14, 1463–1470 (1997).
  Article CAS PubMed Google Scholar
• Fulda, S., Sieverts, H., Friesen, C., Herr, I. & Debatin, K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57, 3823–3829 (1997).
  CAS PubMed Google Scholar
• Castle, V. P. et al. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 143, 1543–1550 (1993).
  CAS PubMed PubMed Central Google Scholar
• Oue, T. et al. In situ detection of DNA fragmentation and expression of bcl-2 in human neuroblastoma: relation to apoptosis and spontaneous regression. J. Pediatr. Surg. 31, 251–257 (1996).
  Article CAS PubMed Google Scholar
• Dole, M. et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 54, 3253–3259 (1994).
  CAS PubMed Google Scholar
• Dole, M. G. et al. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55, 2576–2582 (1995).
  CAS PubMed Google Scholar
• Nakagawara, A. et al. High levels of expression and nuclear localization of interleukin-1β converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 57, 4578–4584 (1997).
  CAS PubMed Google Scholar
• Westermann, F. & Schwab, M. Genetic parameters of neuroblastomas. Cancer Lett. 184, 127–147 (2002).
  Article CAS PubMed Google Scholar
• Brodeur, G. M. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. 11, 1466–1477 (1993). A description of the International Neuroblastoma Staging System currently used throughout the world.
  Article CAS PubMed Google Scholar
• Hann, H. W. L. et al. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma. The Children's Cancer Study Group Experience. Cancer Res. 45, 2843–2848 (1985).
  CAS PubMed Google Scholar
• Zeltzer, P. M., Marangos, P. J., Evans, A. E. & Schneider, S. L. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 57, 1230–1234 (1986).
  Article CAS PubMed Google Scholar
• Ladisch, S. & Wu, Z. L. Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma. Lancet 1, 136–138 (1985).
  Article CAS PubMed PubMed Central Google Scholar
• Quinn, J. J., Altman, A. J. & Frantz, C. N. Serum lactic dehydrogenase, an indicator of tumor activity in neuroblastoma. J. Pediatr. 97, 89–91 (1980).
  Article CAS PubMed Google Scholar
• Shuster, J. J. et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am. J. Clin. Oncol. 15, 295–303 (1992).
  Article CAS PubMed Google Scholar
• Shimada, H. et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl Cancer Inst. 73, 405–413 (1984). The original report of the popular histopathological classification for predicting outcome of neuroblastoma patients. This was subsequently revised into the International Neuroblastoma Pathology Classification.
  Article CAS PubMed Google Scholar
• Shimada, H. et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86, 349–363 (1999).
  Article CAS PubMed Google Scholar
• Shimada, H. et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86, 364–372 (1999).
  Article CAS PubMed Google Scholar
• Combaret, V. et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J. Clin. Oncol. 14, 25–34 (1996).
  Article CAS PubMed Google Scholar
• Castleberry, R. P. et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur. J. Cancer 33, 2113–2116 (1997). First report of an international consensus on neuroblastoma risk groups using a combination of clinical and biological variables.
  Article CAS PubMed Google Scholar
• Beckwith, J. & Perrin, E. In situ neuroblastomas: a contribution to the natural history of neural crest tumors. Am. J. Pathol. 43, 1089–1104 (1963).
  CAS PubMed PubMed Central Google Scholar
• Turkel, S. B. & Itabashi, H. H. The natural history of neuroblastic cells in the fetal adrenal gland. Am. J. Pathol. 76, 225–243 (1975).
  Google Scholar
• Ikeda, Y., Lister, J., Bouton, J. M. & Buyukpamukcu, M. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J. Pediatr. Surg. 16, 636–644 (1981).
  Article CAS PubMed Google Scholar
• Evans, A. E., Gerson, J. & Schnaufer, L. Spontaneous regression of neuroblastoma. Natl Cancer Inst. Monogr. 44, 49–54 (1976).
  CAS PubMed Google Scholar
• Sawada, T. et al. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 53, 2731–2735 (1984). A seminal paper that indicates the potential value of mass screening for early detection of disease to improve the prognosis of neuroblastoma. Subsequent reports from mass screening programmes in Quebec and Germany indicate that there is no impact on mortality.
  Article CAS PubMed Google Scholar
• Takeda, T. et al. Japanese experience of screening. Med. Pediatr. Oncol. 17, 368–372 (1989).
  Article CAS PubMed Google Scholar
• Schilling, F. H. et al. Screening for neuroblastoma. Lancet 344, 1157–1158 (1994).
  Article CAS PubMed Google Scholar
• Woods, W. G. et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 348, 1682–1687 (1996).
  Article CAS PubMed Google Scholar
• Kaneko, Y. et al. Chromosomes and screening for neuroblastoma. Lancet 1, 174–175 (1988).
  Article CAS PubMed Google Scholar
• Hayashi, Y., Inaba, T., Hanada, R. & Yamamoto, K. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening. J. Pediatr. 112, 567–571 (1988).
  Article CAS PubMed Google Scholar
• Hayashi, Y., Hanada, R. & Yamamoto, K. Biology of neuroblastomas in Japan found by screening. Am. J. Pediatr. Hematol. Oncol. 14, 342–347 (1992).
  Article CAS PubMed Google Scholar
• Brodeur, G. M. et al. Biological aspects of neuroblastomas identified by mass screening in Quebec. Med. Pediatr. Oncol. 36, 157–159 (2001).
  Article CAS PubMed Google Scholar
• Woods, W. G. et al. Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346, 1041–1046 (2002).
  Article PubMed Google Scholar
• Schilling, F. H. et al. Neuroblastoma screening at one year of age. N. Engl. J. Med. 346, 1047–1053 (2002).
  Article PubMed Google Scholar
• Kaneko, Y., Kobayashi, H., Maseki, N., Nakagawara, A. & Sakurai, M. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants. Int. J. Cancer 80, 54–59 (1999).
  Article CAS PubMed Google Scholar
• Tajiri, T. et al. Clinical and biologic characteristics for recurring neuroblastoma at mass screening cases in Japan. Cancer 92, 349–353 (2001).
  Article CAS PubMed Google Scholar
• van Limpt, V. et al. SAGE analysis of neuroblastoma reveals a high expression of the human homologue of the Drosophila Delta gene. Med. Pediatr. Oncol. 35, 554–558 (2000).
  Article CAS PubMed Google Scholar
• Spieker, N. et al. The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. Genomics 71, 214–221 (2001).
  Article CAS PubMed Google Scholar
• Khan, J. et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Med. 7, 673–679 (2001).
  Article CAS PubMed Google Scholar
• Truckenmiller, M. E. et al. Gene expression profile in early stage of retinoic acid-induced differentiation of human SH-SY5Y neuroblastoma cells. Restor. Neurol. Neurosci. 18, 67–80 (2001).
  CAS PubMed Google Scholar
• Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G. & Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985–2995 (1997). First report of a transgenic mouse that overexpresses the MYCN proto-oncogene under the control of a tyrosine kinase promoter and develops neuroblastoma with high frequency.
  Article CAS PubMed PubMed Central Google Scholar
• Weiss, W. A., Godfrey, T., Francisco, C. & Bishop, J. M. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res. 60, 2483–2487 (2000).
  CAS PubMed Google Scholar
• Norris, M. D., Burkhart, C. A., Marshall, G. M., Weiss, W. A. & Haber, M. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med. Pediatr. Oncol. 35, 585–589 (2000).
  Article CAS PubMed Google Scholar
• Sidell, N., Altman, A., Haussler, M. R. & Seeger, R. C. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp. Cell Res. 148, 21–30 (1983).
  Article CAS PubMed Google Scholar
• Thiele, C. J., Reynolds, C. P. & Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313, 404–406 (1985).
  Article CAS PubMed Google Scholar
• Reynolds, C. P. et al. Comparison of 13-_cis_-retinoic acid to _trans_-retinoic acid using human neuroblastoma cell lines. Prog. Clin. Biol. Res. 385, 237–244 (1994).
  CAS PubMed Google Scholar
• Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-_cis_-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165–1173 (1999). First clinical trial indicating that a survival advantage exists for the treatment of neuroblastoma patients with retinoic acid following bone-marrow transplantation.
  Article CAS PubMed Google Scholar
• Lovat, P. E. et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp. Cell Res. 260, 50–60 (2000).
  Article CAS PubMed Google Scholar
• Ponzoni, M. et al. Differential effects of _N_-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 55, 853–861 (1995).
  CAS PubMed Google Scholar
• Reynolds, C. P. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep. 2, 511–518 (2000).
  Article CAS PubMed Google Scholar
• Galderisi, U., Cascino, A. & Giordano, A. Antisense oligonucleotides as therapeutic agents. J. Cell Physiol. 181, 251–257 (1999).
  Article CAS PubMed Google Scholar
• Evans, A. E. et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin. Cancer Res. 5, 3594–3602 (1999). First report of a tyrosine kinase inhibitor that is selective for Trk receptors with potential use in treating neuroblastomas.
  CAS PubMed Google Scholar
• Meitar, D., Crawford, S. E., Rademaker, A. W. & Cohn, S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14, 405–414 (1996). Definitive report correlating tumour angiogenesis with high-risk features and outcome in neuroblastomas. This report serves as the rationale for anti-angiogenesis therapy in high-risk neuroblastomas.
  Article CAS PubMed Google Scholar
• Wassberg, E., Pahlman, S., Westlin, J. E. & Christofferson, R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr. Res. 41, 327–333 (1997).
  Article CAS PubMed Google Scholar
• Katzenstein, H. M. et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin. Cancer Res. 5, 4273–4278 (1999).
  CAS PubMed Google Scholar
• Shusterman, S., Grupp, S. A. & Maris, J. M. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med. Pediatr. Oncol. 35, 673–676 (2000).
  Article CAS PubMed Google Scholar
• Erdreich-Epstein, A. et al. Integrins α(v)β3 and α(v)β5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 60, 712–721 (2000).
  CAS PubMed Google Scholar
• Jouanneau, E. et al. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J. Neurooncol. 51, 11–18 (2001).
  Article CAS PubMed Google Scholar
• Kim, E. S. et al. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J. Pediatr. Surg. 37, 518–522 (2002).
  Article PubMed Google Scholar
• Davidoff, A. M., Leary, M. A., Ng, C. Y. & Vanin, E. F. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J. Pediatr. Surg. 36, 30–36 (2001).
  Article CAS PubMed Google Scholar
• Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Frost, J. D. et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80, 317–333 (1997).
  Article CAS PubMed Google Scholar
• Yu, A. L. et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 16, 2169–2180 (1998).
  Article CAS PubMed Google Scholar
• Cheung, N. K., Kushner, B. H., Yeh, S. D. & Larson, S. M. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int. J. Oncol. 12, 1299–1306 (1998).
  CAS PubMed Google Scholar
• De Kraker, J. et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur. J. Cancer 31A, 600–602 (1995).
  Article CAS PubMed Google Scholar
• Matthay, K. K. et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J. Clin. Oncol. 16, 229–236 (1998).
  Article CAS PubMed Google Scholar
• Yanik, G. A. et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J. Clin. Oncol. 20, 2142–2149 (2002).
  Article CAS PubMed Google Scholar
• Fitzek, M. M. et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 94, 2623–2634 (2002).
  Article PubMed Google Scholar
• Luttikhuis, M. E. et al. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br. J. Cancer 85, 531–537 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Bhattacharyya, N., Thornton, A. F., Joseph, M. P., Goodman, M. L. & Amrein, P. C. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch. Otolaryngol. Head Neck Surg. 123, 34–40 (1997).
  Article CAS PubMed Google Scholar
• Gurney, J. G. et al. Infant cancer in the US: histology-specific incidence and trends, 1973 to 1992. J. Pediatr. Hematol. Oncol. 19, 428–432 (1997).
  Article CAS PubMed Google Scholar
• Schmidt, M. L. et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J. Clin. Oncol. 18, 1260–1268 (2000).
  Article CAS PubMed Google Scholar